U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557602) titled 'mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults' on April 22.
Brief Summary: This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Study Start Date: May 04
Study Type: INTERVENTIONAL
Condition:
EBV
Intervention:
BIOLOGICAL: VXCO-102
Sterile liquid for injection
BIOLOGICAL: Placebo
0.9% sodium chloride (BP grade)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vaccine Company, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....